Systemic Aspergillosis And Systemic Candidiasis Market Analysis, Top Drivers, Key Players, Segmentation And Forecast To 2033

"The new report published by The Business Research Company, titled Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the systemic aspergillosis and systemic candidiasis market size has grown strongly in recent years. It will grow from $6.82 billion in 2023 to $7.2 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The systemic aspergillosis and systemic candidiasis market size is expected to see steady growth in the next few years. It will grow to $8.63 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp

Rising Incidence Of Fungal Diseases Spurs Growth In The Systemic Aspergillosis And Systemic Candidiasis Market
The increase in the incidence of fungal diseases is expected to propel the growth of the systemic aspergillosis and systemic candidiasis market going forward. Fungal diseases refer to infections caused by fungi that can affect various body parts, resulting in multiple symptoms and complications. These diseases include cutaneous skin infections, respiratory infections, and systemic infections. Fungal diseases are treated with antifungal medications such as oral azoles, voriconazole, and liposomal amphotericin B. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, in the US, the clinical cases of Candida auris, an emerging fungus, increased from 476 in 2019 to 1,471 in 2021. Screening cases increased threefold from 2020 to 2021, to 4,041. Therefore, the increase in the incidence of fungal disease is driving the growth of the systemic aspergillosis and systemic candidiasis market.

Product Innovation Drive Advancements In The Systemic Aspergillosis And Systemic Candidiasis Markets
Product innovation is a key trend gaining popularity in the systemic aspergillosis and systemic candidiasis markets. Major companies operating in the systemic aspergillosis and systemic candidiasis markets are focused on developing innovative products to sustain their position in the market. For instance, in October 2021, Intas Pharmaceuticals Limited, an India-based pharmaceutical formulation development, manufacturing, and marketing company, launched the world's first Super Bioavailable Itraconazole-SB 100mg under the brand name Itaspor-SB Forte/Subawin. It will cut the dosing in half, and patients can consume it with or without food, with just water. The conventional Itraconazole mainstay medicine to combat fungal infection has a large outcome variance and low patient compliance.

The systemic aspergillosis and systemic candidiasis market covered in this report is segmented -

1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications
3) By End User: Clinic, Hospital, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12148&type=discount

Major companies operating in the systemic aspergillosis and systemic candidiasis market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd, Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., NovaDigm Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, N8 Medical LLC

Contents of the report:
1. Executive Summary
2. Systemic Aspergillosis And Systemic Candidiasis Market Report Structure
3. Systemic Aspergillosis And Systemic Candidiasis Market Trends And Strategies
4. Systemic Aspergillosis And Systemic Candidiasis Market - Macro Economic Scenario
5. Systemic Aspergillosis And Systemic Candidiasis Market Size And Growth
…..
27. Systemic Aspergillosis And Systemic Candidiasis Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemic-candidiasis-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.